✦ LIBER ✦

Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B

✍ Scribed by Sonali M. Smith; David Grinblatt; Jeffrey L. Johnson; Donna Niedzwiecki; David Rizzieri; Nancy L. Bartlett; Bruce D. Cheson; for the Cancer; Leukemia Group B

Book ID: 108675557
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 111 KB
Volume: 140
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2007.06937.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of etoposide and cisplati

Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non-Hodgkin's lymphoma: Cancer and leukemia group B study 8351

✍ Rybak, Mary Ellen ;Anderson, James ;Kaplan, Richard ;Budman, Daniel R. ;Vincigue 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB

## Abstract A phase‐II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed non‐Hodgkin's lymphoma (NHL) to assess the activity of the combination of etoposide and cisplatin. Sixty‐five patients were entered on study, and 51 patients were evaluated

Gemcitabine, dexamethasone, and cisplati

Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma : A Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)

✍ Michael Crump; Tara Baetz; Stephen Couban; Andrew Belch; Deborah Marcellus; Kang 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views